

Troy Albert Reaves, Jr., Ph.D.

Personal Data

Residence: 6625 Ridgefield Drive
Alpharetta, Georgia 30005
Telephone: Home: 770 205 1495
Office: 770 905 1860

Business Experience

NOVARTIS OPHTHALMICS; Atlanta, Georgia	8/91 – Present
<u>Senior Director, Clinical R&D</u>	8/99 - present
<u>Head, Clinical Project Management</u>	11/97 – 8/99
<u>Director, Clinical R&D</u>	8/91 – 11/97

XENON VISION, INC.; Alachua, Florida	5/89 - 8/91
<u>Director, Clinical and Regulatory Affairs</u>	

ALCON LABORATORIES, INC.; Fort Worth, Texas	5/84 - 5/89
<u>Manager, Glaucoma Clinical Research</u>	10/86 – 5/89
<u>Manager, Cornea/External Disease Clinical Research</u>	10/84 – 10/86
<u>CRA II, Cornea/External Disease Clinical Research</u>	5/84 – 10/84

WCC, INC.; Fort Worth, Texas	9/82 - 5/84
<u>General partner.</u>	

UNIVERSITY OF NORTH CAROLINA; Chapel Hill, N.C.	8/76 - 9/82
<u>Assistant Professor, Neurology & Neurobiology</u>	

UNIVERSITY OF ILLINOIS; Urbana, Illinois	8/75 - 8/76
<u>Visiting Assistant Professor, Physiology & Biophysics</u>	

Education

University of Illinois; Urbana, Illinois

Ph.D., Physiology and Biophysics, 1976 [Neuroscience]

North Texas State University, Denton, Texas

M.S., Biology, 1971 [Cardiovascular Physiology]

West Texas State University, Canyon, Texas

B.S., Biology, 1969

Professional Affiliations

American Academy of Ophthalmology (AAO)

Associates in Clinical Pharmacology (ACP)

Association for Research in Vision and Ophthalmology (ARVO)

Contact Lens Association of Ophthalmologists (CLAO)

Drug Information Association (DIA)

Publications

- Over 60 publications in refereed journals (List provided on request)
- Over 2 dozen publications in ophthalmology

BIBLIOGRAPHY

1. Reaves, T. A., W. C. Hartner, and J. E. Heath. Interstitial fluid pressure and vasomotor responses in bats. American Journal Physiology 226:353-356, 1974.
2. Reaves, Jr., T. A., and J. E. Heath. Interval coding of temperature by CNS neurons in thermoregulation. Nature 257:688-690, 1975.
3. Reaves, T. A. and J. E. Heath. Neural correlates of thermoregulatory behavior. Federation Proceedings 34:455, 1975.
4. Reaves, T. A. and J. E. Heath. Rate independent coding of temperature by preoptic neurons. Physiologist 18:363, 1975.
5. Reaves, T. A. and J. E. Heath. A thermoregulatory characteristic: gain of preoptic area neurons. Federation Proceedings 35:481, 1976.
6. Reaves, Jr., T. A. Gain of thermosensitive neurons in the preoptic area of the rabbit, Orcytolagus cuniculus. Journal Thermal Biology 2:31-33, 1977.
7. Reaves, T. A. and J. N. Hayward. Immunocytochemical study of vasopressinergic and oxytocinergic neurons in the supraoptic, paraventricular and accessory nuclei of the cat hypothalamus. Anatomical Record 190:518, 1978.
8. Reaves, Jr., T. A. and J. N. Hayward. Immunocytochemical study of vasopressinergic and oxytocinergic neurons in rat hypothalamic supraoptic accessory nucleus. Federation Proceedings 37:437, 1978.
9. Reaves, Jr., T. A., H-M. Liu, M. Qasim and J. N. Hayward. Vasopressin, cardiovascular and behavioral responses to nicotine in the cat. Society Neuroscience Abstracts 4:353, 1978.
10. Reaves, Jr., T. A. and J. N. Hayward. Hypothalamic and extra-hypothalamic thermoregulatory centers. In: Body Temperature: Regulation, Drug Effects, and Therapeutic Implications, P. Lomas and E. Schonbaum (eds.), Marcel Dekker, Inc., New York, 1979, pp.39-70.
11. Reaves, Jr., T. A. and J. N. Hayward. Immunocytochemical identification of vasopressinergic and oxytocinergic neurons in the hypothalamus of the cat. Cell Tissue Research 196:117-122, 1979.
12. Reaves, Jr., T. A. and J. N. Hayward. Chemical identification of physiologically-defined dye-injected neuroendocrine cells in preoptic nucleus of goldfish hypothalamus. Endocrine Society Abstracts 61:160, 1979.
13. Reaves, Jr., T. A. and J. N. Hayward. Immunocytochemical identification of enkephalinergic neurons in the hypothalamic magnocellular preoptic nucleus of the goldfish, Carassius auratus. Cell Tissue Research 200:147-151, 1979.
14. Reaves, Jr., T. A. and J. N. Hayward. Isotocinergic neurons in the goldfish hypothalamus: Physiology and morphological studies on chemically identified cells. Cell Tissue Research 202:17-26, 1979.

BIBLIOGRAPHY - continued

15. Reaves, Jr., T. A. and J. N. Hayward. Enkephalin neurons in goldfish hypothalamus: Physiology and morphology studied by intracellular recording and Lucifer Yellow marking. Society Neuroscience Abstracts 5:537, 1979.
16. Reaves, Jr., T. A. and J. N. Hayward. Intracellular dye-marked enkephalin neurons in the magnocellular preoptic nucleus of the goldfish hypothalamus. Proceedings National Academy Sciences 76:6009-6011, 1979.
17. Hayward, J. N. and T. A. Reaves, Jr. Electrophysiology of hypothalamic magnocellular neuroendocrine cells. In: Brain and Pituitary Peptides. Wuttke, Voigt, Weindl and Dries (eds.), Karger, Basel, 1980, pp 110-117.
18. Reaves, Jr., T. A. and J. N. Hayward. Functional and morphological studies of peptide-containing neuroendocrine cells in goldfish hypothalamus. Journal Comparative Neurology 193:777-778, 1980.
19. Greenwood, R. S., S. Godar, T. A. Reaves, Jr. and J. N. Hayward. Cholecystokinin in the hippocampal formation and its connections. Society Neuroscience Abstracts 6:620, 1980.
20. Hayward, J. N. and T. A. Reaves, Jr. The "Endocrine" brain: electrophysiological aspects. In: Endocrine Functions of the Brain, M. Motta (ed.), Raven Press, New York, 1980, pp. 21-41.
21. Hayward, J. N. and T. A. Reaves, Jr. Functional and morphological aspects of peptidergic magnocellular neuroendocrine cells in the hypothalamus. In: Antidiuretic Hormone, Share and Yoshida (eds.), University Park Press, Baltimore, 1980, pp. 19-32.
22. Reaves, T. A., Jr., H-M. Liu, M. Qasim and J. N. Hayward. Osmotic regulation of vasopressinergic neurons in the cat. American Journal Physiology 240:E108-111, 1981.
23. Berk, M. L., T. A. Reaves, Jr., J. N. Hayward, and J. A. Finkelstein. Immunocytochemical localization of neurophysin, vasotocin and oxytocin-like peptides in the avian diencephalon. Anatomical Record 199:27A, 1981.
24. Reaves, T. A., Jr., H-M. Liu, M. Qasim and J. N. Hayward. Vasopressin release by nicotine in the cat. Peptides 2:13-17, 1981.
25. Reaves, T. A., Jr., and J. N. Hayward. Dye-marked paraventricular neuroendocrine cells in vivo in cat hypothalamus. Neuroscience Letters 25:263-267, 1981.
26. Reaves, Jr., T. A., R. Cumming and J. N. Hayward. Light and EM localization of HRP-injected, physiologically identified MGC neuroendocrine cells in goldfish preoptic nucleus. Society Neuroscience Abstracts 7:1981.
27. Cumming, R., T. A. Reaves, Jr. and J. N. Hayward. Electron microscopic immunocytochemical characterization of enkephalinergic neurons and synapses within the preoptic nucleus of the goldfish. Society Neuroscience Abstracts 7, 1981.
28. Greenwood, R. S., S. E. Godar, T. A. Reaves, Jr., and J. N. Hayward. Cholecystokinin in hippocampal pathways. Journal Comparative Neurology 203:335-350, 1981.

BIBLIOGRAPHY - continued

29. Berk, M. L., T. A. Reaves, Jr., J. N. Hayward, and J. A. Finkelstein. The localization of vasotocin and neurophysin neurons in the diencephalon of the pigeon, Columbia Livia. Journal Comparative Neurology 204:392-406, 1982.
30. Cumming, R., T. A. Reaves, Jr., and J. N. Hayward. Ultrastructural immunocytochemical localization of enkephalin in the goldfish preoptic nucleus. Neuroscience Letters 27:313-318, 1982.
31. Reaves, Jr., T. A., M. T. Libber and J. N. Hayward. Supraoptic neurons in rat hypothalamo-neurohypophysial explants: Ultrastructural and immunocytochemical characterization of electrophysiologically-identified magnocellular neurons. Society Neuroscience Abstracts 8:1982.
32. Reaves, T. A., Jr., Cumming, R. and J. N. Hayward. Light- and electron-microscopic characterization of electrophysiologically-identified, HRP-injected magnocellular neuroendocrine cells in goldfish preoptic nucleus. Neuroscience 7:1545-1557, 1982.
33. Cumming, R., T. A. Reaves, Jr., and J. N. Hayward. Ultrastructural immunocytochemical characterization of isotocin, vasotocin and neurophysin neurons in the magnocellular preoptic nucleus of the goldfish. Cell Tissue Research 223:685-694, 1982.
34. Reaves, Jr., T. A., A. Hou-Yu, E. A. Zimmerman and J. N. Hayward. Vasopressin neurons in rat supraoptic nucleus: Antidromic identification, Lucifer Yellow injection and immunocytochemical identification in the hypothalamo-neurohypophysial explant. Physiologist 25:316, 1982.
35. Reaves, T. A., Jr., Cumming, R., Libber, M. T. and J. N. Hayward. A technique combining intracellular dye-marking, immunocytochemical identification and ultrastructural analysis of physiologically-identified single neurons, Neuroscience Letters 29:195-199, 1982.
36. Reaves, Jr., T. A. and J. E. Heath. Thermosensitive characteristics of a preoptic area neuron recorded over a 20 day period in the rabbit. Brain Research Bulletin 10:30-41, 1983.
37. Reaves, Jr., T. A., R. Cumming, M. T. Libber and J. N. Hayward. Immunocytochemical identification of intracellularly dye-marked neurons: A double-labeling technique for light and electron microscopic analysis. In: Techniques in Immunocytochemistry, G. R. Bullock and P. Petrusz (ed.), Vol. 2. Academic Press, London, 1983, pp. 70-84.
38. Reaves, Jr., T. A., Hou-Yu, A., Zimmerman, E. A. and J. N. Hayward. Supraoptic neurons in the rat hypothalamo-neurohypophysial explant: double-labeling with Lucifer Yellow injection and immunocytochemical identification of vasopressin and neurophysin-containing neuroendocrine cells. Neuroscience Letters 37:137-142, 1983.
39. Hayward, J. N., T. A. Reaves, Jr., R. S. Greenwood and R. B. Meeker. Neuroendocrine cells In Vitro: electrophysiology, triple-labeling with dye-marking, immunocytochemical and ultrastructural analysis and hormone release. In P. M. Conn (ed.) Methods in Enzymology, Hormone Action: Neuroendocrine Peptides, academic Press, Vol. 103, 1984, pp. 132-168.

BIBLIOGRAPHY - continued

40. Stark, W. J., Fagadau, W. R., Stewart, R. H., Crandall, A. S., defaller, J. M., T. A. Reaves, Jr. and P. E. Klein. Reduction of pupillary constriction during cataract surgery using suprofen. Archives Ophthalmology 104:364-366, 1986.
41. Buckley, D. C., Caldwell, D. R. and T. A. Reaves, Jr. Treatment of vernal conjunctivitis with suprofen, a topical nonsteroidal anti-inflammatory agent. Invest. Ophthalmol. Vis. Sci. 27 (Suppl.):29, 1986.
42. Aoki, K. R., Reaves, T. A. and L. M. DeSantis. Topical ocular anti-inflammatory efficacy of suprofen. Abstract to: Inflammation Research Association 3rd International Conference, White Haven, PA. October 19-23, 1986.
43. Wood, T. S., Bowman, R. W., Reaves, Jr., T. A. and J. P. McCulley. Giant papillary conjunctivitis: Treatment with suprofen, a topical nonsteroidal anti-inflammatory agent. Ophthalmology 95:822-826, 1988.
44. Leibowitz, H., Rosenthal, A., Reaves, T. A. Gel tears for the treatment of dry eyes. ACTA XXV Concilium Ophthalmologicum Proceedings of the XXV International Congress of Ophthalmology, Rome, May 4-10, 1986, Kugler Publications/Ghedini Editore, Amsterdam, Berkeley, Milano, Ppgs. 1216-1218, 1988.
45. Rosenthal, A. L., Reaves, T. A. Effectiveness of suprofen for treatment of vernal and giant papillary conjunctivitis. ACTA XXV Concilium Ophthalmologicum Proceedings of the XXV International Congress of Ophthalmology, Rome, May 4-10, 1986, Kugler Publications/Ghedini Editore, Amsterdam, Berkeley, Milano, Ppgs. 1305-1310, 1988.
46. Rosenthal, A. L., defaller, J. M, Reaves, T. A. Clinical evaluation of suprofen in cataract surgery. ACTA XXV Concilium Ophthalmologicum Proceedings of the XXV International Congress of Ophthalmology, Rome, May 4-10, 1986, Kugler Publications/Ghedini Editore, Amsterdam, Berkeley, Milano, Ppgs 2481-2484, 1988.
47. Robin, A. L., Brown, R. H., Reaves, T. A. Reduction in the intraocular pressure elevation after anterior segment laser surgery by a topical alpha agonist: ALO2145. Proceedings from the European Glaucoma Society, 3rd Congress, Estoril, Portugal, May 23-26, 1988.
48. Abrams, D. A., Robin, A. L., Crandall, A. S., Caldwell, D. R., Schnitzer, D. B., Pollack, I. P., Rader, J. E., Reaves, T. A. Jr. A Limited Comparison of Apraclonidine's Dose Response in Subjects with Normal or Increased Intraocular Pressure. Am. J. Ophthalmol. 108:230-237, 1989.
49. Abrams, D. A., Robin, A. L., Pollack, I.P., Crandall, A. S., Caldwell, D. R., Schnitzer, D. B., Rader, J. E., Reaves, T. A. Jr. A Limited Comparison of Apraclonidine's Dose Response in Subjects with Normal or Elevated Intraocular Pressures. Invest. Ophthalmol. Vis. Sci. 30 (Suppl.): 98, 1989.
50. Winwood, D. and Reaves, T.A. Review of "Topically Active Carbonic Anhydrase Inhibitors, Parts 1 and 2", Chemtracts-Organic Chemistry 3: 213-217, 1990.
51. Laibovitz, R.A., Ghormley, N.R., Insler, M.S., Cartee, L., Reaves, T.A. Treatment of giant papillary conjunctivitis with loteprednol etabonate, a novel corticosteroid. Invest. Ophthalmol. Vis. Sci. 32 (Suppl.):734, 1991.
52. Leibowitz, H.M., Kupferman, A., Ryan, W.J., Reaves, T.A., Howes, J. Corneal anti-inflammatory efficacy of loteprednol etabonate: a new steroidal "soft drug". Invest. Ophthalmol. Vis. Sci. 32 (Suppl.):735, 1991.
53. Druzgala, P.D., Wu, W.M., Winwood, D., Howes, J.F., Reaves, T.A. Ocular absorption and distribution of

- loteprednol etabonate: a 'soft' steroid. Invest. Ophthalmol. Vis. Sci. 32 (Suppl.):735, 1991.
54. Keates, E.U., Druzgala, P.D., Howes, J.F., Reaves, T.A. Loteprednol etabonate: a new steroid without ocular hypertensive effect. Invest. Ophthalmol. Vis. Sci. 32 (Suppl.):947, 1991.
 55. Osher, R.H., Vickers, F.F., Powell, M.L., Shlevin, H.S., Reaves, T.A. Ocular absorption of diclofenac sodium in patients scheduling cataract surgery. Invest. Ophthalmol. Vis. Sci. 33 (Suppl.): 997, 1992.
 56. McCarey, B.E., Napalkov, J.A., Pippen, P.A., Reaves, T.A. Corneal wound healing strength with topical antiinflammatory drugs. Invest. Ophthalmol. Vis. Sci. 34 (Suppl.):1321, 1993.
 57. Reaves, T.A. The clinical properties of currently available NSAIDs. In: Proceedings of the Ophthalmic NSAID Roundtable, Dallas, November 1992, Edited by Leon D. Solomon, MD, Medicopea, Montreal, pages 27-29, 1993.
 58. McCarey, B.E., Reaves, T.A. Noninvasive measurement of corneal epithelial permeability. Invest. Ophthalmol. Vis. Sci. 35 (Suppl.):1945, 1994.
 59. Nassaralla, J.J., Szerenyi, K., Wang, X.W., Nassaralla, B.A., Reaves, T.A., McDonnell, P.J. Effect of diclofenac on corneal haze. Invest. Ophthalmol. Vis. Sci. 35 (Suppl.):3495, 1994.
 60. McCarey, B.E., Reaves, T.A. Noninvasive measurement of corneal epithelial permeability. Curr. Eye Res. 14: 505-510, 1995.
 61. Nassaralla, B.A., Szerenyi, K., Wang, X.W., Reaves, T.A., McDonnell, P.J. Effect of diclofenac on corneal haze after photorefractive keratectomy in rabbits. Ophthalmology 102(3): 469-474, 1995.
 62. McCarey, B.E., Reaves, T.A. Artificial tear preparations affect on *in vivo* corneal epithelial permeability. Invest. Ophthalmol. Vis. Sci. 36 (Suppl.): S995, 1995.
 63. Nassaralla, B.A., Wang, X.W., Wee, W.R., Pinheiro, M., Santos, P.M., Nassaralla, J.J., Reaves, T.A., Jauch, A., McDonnell, P.J. Invest. Ophthalmol. Vis. Sci. 36 (Suppl.): S1019, 1995.
 64. Laibovitz, R.A., Koester, J.M., Schaich, L., Reaves, T.A. Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J. Ocular Pharmacol. Therapeutics 11(3): 361-368, 1995.
 65. Nassaralla, B.A., dos Santos, P.M., Wang, X.W., Wee, W.R., Pinheiro, Jr., M., Nassaralla, Jr., J.J., Reaves, T.A., Jauch, A., McDonnell, P. Estudo experimental da eficacia clinica e microbiologica da associacao do diclofenaco sodico e sulfata de gentamicina no tratamento de ceratite por *Pseudomonas aeruginosa*. [Clinical and microbiological effect of sodium diclofenac on gentamicin treatment of experimental *Pseudomonas aeruginosa* keratitis] Arq. Bras. Oftal. 60(5): 516 – 521, 1997.
 66. McCarey, B.E., Reaves, T.A. Effect of tear lubricating solutions on *in vivo* corneal epithelial permeability. Curr Eye Res 16(1): 44-50, 1997.
 67. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Archives Ophthalmology 119(2):198-207, 2001.
 68. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial–VIP report no. 1. Ophthalmology 108(5):841-852, 2001.
 69. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal

neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 131(5):541-560, 2001.

70. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22(1):6-18, 2002.
71. Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH Jr, Sickenberg M, Sternberg P Jr, Aaberg TM Sr, Aaberg TM Jr, Reaves TA; Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 109(8): 1499 – 505, 2002.
72. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Archives Ophthalmology 120(11):1443-54, 2002.
73. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Archives Ophthalmology 120(10):1307 - 1314, 2002.
74. Anand R, Bressler NM, Bressler SB, Gray TE, Harvey P, Haynes L, Koester JM, Manos KS, Miller JW, Murphy S, Reaves A, Sickenberg M, Singerman LJ, Strong A, Stur M; "Improvement After Verteporfin Therapy" Writing Committee for TAP Study Group. Improvement after verteporfin therapy. Archives Ophthalmology 121(3): 415 - 416, 2003.
75. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology 110(4):667 - 673, 2003.